Phase I trial to evaluate safety, pharmacokinetics, and efficacy of sorafenib combined with docetaxel in patients with advanced, refractory solid tumors

被引：0
|
作者：
Awada, A.
Hendlisz, A.
Whenham, N.
Gil, T.
Christensen, O.
Lathia, C.
Bartholomeus, S.
Delabaye, I.
De Valeriola, D.
Brendel, E.
Delaunoit, T.
Piccart, M.
机构：
[1] Jules Bordet Inst, Brussels, Belgium
[2] Bayer Pharmaceut Corp, West Haven, CT USA
[3] Bayer HealthCare, Wuppertal, Germany
来源：
ANNALS OF ONCOLOGY | 2007年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：39 / 39
页数：1
相关论文
共 50 条
  • [31] Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics
    Sunakawa, Yu
    Furuse, Junji
    Okusaka, Takuji
    Ikeda, Masafumi
    Nagashima, Fumio
    Ueno, Hideki
    Mitsunaga, Shuichi
    Hashizume, Kensei
    Ito, Yuichiro
    Sasaki, Yasutsuna
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (01) : 104 - 112
  • [32] Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics
    Yu Sunakawa
    Junji Furuse
    Takuji Okusaka
    Masafumi Ikeda
    Fumio Nagashima
    Hideki Ueno
    Shuichi Mitsunaga
    Kensei Hashizume
    Yuichiro Ito
    Yasutsuna Sasaki
    Investigational New Drugs, 2014, 32 : 104 - 112
  • [33] Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors
    Liu, Jingrui
    Zhang, Hong
    Zhu, Xiaoxue
    Chen, Hong
    Li, Xiaojiao
    Ding, Yanhua
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [34] Phase I trial of weekly irinotecan plus docetaxel in patients with advanced solid tumors.
    Font, A
    Sánchez, JM
    Guillot, M
    Abad, A
    Taron, M
    Margelí, M
    Barnadas, A
    Rosell, R
    ANNALS OF ONCOLOGY, 2000, 11 : 141 - 141
  • [35] Phase I Clinical Trial of Pegylated Liposomal Doxorubicin and Docetaxel in Patients With Advanced Solid Tumors
    Iqbal, Syma
    Tsao-Wei, Denice D.
    Quinn, David I.
    Gitlitz, Barbara J.
    Groshen, Susan
    Aparicio, Ana
    Lenz, Heinz Josef
    El-Khoueiry, Anthony
    Pinski, Jacek
    Garcia, Agustin A.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2011, 34 (01): : 27 - 31
  • [36] Phase I trial of docetaxel (DOTAX) and topotecan hydrochloride (TOPO) in patients with advanced solid tumors
    Tkaczuk, K
    Brooks, S
    Minford, J
    Meisenberg, B
    Fedenko, K
    Sivasailam, S
    Tait, N
    VanEcho, D
    ANNALS OF ONCOLOGY, 1998, 9 : 134 - 134
  • [37] Phase I clinical trial of weekly combined paclitaxel plus docetaxel in patients with solid tumors
    Lokich, J
    CANCER, 2000, 89 (11) : 2309 - 2314
  • [38] Phase I trial of sorafenib, bevacizumab, and temsirolimus in advanced solid tumors.
    Westin, Shannon Neville
    Smart, Melody L.
    Pal, Navdeep
    Urbauer, Diana L.
    Janku, Filip
    Wheler, Jennifer J.
    Piha-Paul, Sarina Anne
    Naing, Aung
    Tsimberidou, Apostolia Maria
    Fu, Siqing
    Falchook, Gerald Steven
    Hong, David S.
    Zinner, Ralph
    Subbiah, Vivek
    Culotta, Kirk Salvatore
    Lu, Karen H.
    Coleman, Robert L.
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [39] A phase 1 study evaluating the pharmacokinetics (PK), safety, and efficacy of regorafenib (REG) in Chinese patients with advanced, refractory solid tumors
    Cao, J.
    Ji, D.
    Shen, W.
    Wang, Q.
    Liu, Y.
    Lu, D.
    Sturm, I.
    Huang, F.
    Cleton, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [40] Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors
    Reid, JM
    Qu, WC
    Safgren, SL
    Ames, MM
    Krailo, MD
    Seibel, NL
    Kuttesch, J
    Holcenberg, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) : 2445 - 2451
12345